Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Europe down but oil and mining stocks boost FTSE

Wed, 23rd Jun 2021 12:11

(Alliance News) - The FTSE 100 climbed midday Wednesday, with share price gains for miners and oil stocks ensuring the London's blue-chip index outperformed continental peers, following a raft of mixed PMI readings across the globe.

"Experiences throughout Australia, Japan, and Europe highlight a tough June after many surveys fell short. From a UK perspective, the decline in services growth is worrying, with exports falling for the second-consecutive month," IG market analyst Joshua Mahony commented.

"From a UK perspective, the decline in services growth is worrying, with exports falling for the second-consecutive month. One common theme appears to be the impact of rising prices, with input costs rising at the fastest pace in 13 years."

The FTSE 100 index was up 24.87 points, or 0.4%, at 7,114.88 on Wednesday at midday. The mid-cap FTSE 250 index was up just 8.18 points 22,687.82. The AIM All-Share index was up 2.70 points, or 0.2%, at 1,224.85.

The Cboe UK 100 index was up 0.3% at 708.55. The Cboe 250 was 0.1% higher at 20,378.93, and the Cboe Small Companies up 0.4% at 15,348.99.

The UK's flash composite output index, a weighted average of the services and manufacturing readings, remained above the 50.0 no-change mark but fell to a two-month low of 61.7 points in June, from May's 62.9 tally.

Earlier figures showed Japan's private sector remained in contraction, though the eurozone's flash composite PMI increased to 59.2 in June from 57.1 in May, its highest since June 2006.

The pound was quoted at USD1.3967 midday Wednesday following the PMI data, up from USD1.3927 at the London equities close on Tuesday. The euro stood at USD1.1946, up from USD1.1905.

In mainland Europe, the CAC 40 in Paris was down 0.4%, while the DAX 30 in Frankfurt was down 0.5%.

The luxury retail sector held back the blue-chip benchmark in Paris. Kering was down 2.6%, Hermes International 1.6% lower and LVMH fell 1.3%.

In London, Burberry was down 0.1% after HSBC cut the stock to Hold from Buy.

Brent oil was quoted at USD75.44 a barrel, up from USD74.91.

ActivTrades analyst Pierre Veyret explained: "Most oil traders are also paying attention to the ongoing talks with Iran where an agreement with another superpower could quickly lead to a flood in global supply and seriously dent the current rally. Investors will also keep an eye on today's US crude oil inventories where a significant increase is widely expected."

Royal Dutch Shell A shares rose 1.8% in London and the oil major's B stock was up 1.9%. In addition, Societe Generale raised Shell's A shares to Buy from Hold. Peer BP was trading 1.3% higher.

Rio Tinto climbed 1.0%, Anglo American was up 1.1% and BHP rose 0.7% during a largely positive session for the mining sector.

Phoenix Group shares fell 3.3% to 670.20p, the worst blue-chip performer in London. Swiss Re said it has sold a 6.6% stake in Phoenix Group for GBP437 million, offloading half the stake it acquired after selling its ReAssure Group subsidiary to Phoenix last summer.

Swiss Re sold 66.2 million shares at 660p each, and will hold a 6.6% stake following completion of the sale. Prior to the transaction, Swiss Re held a near 13.3% stake in Phoenix Group.

Phoenix was not a party to the placing and will not receive any proceeds.

As Swiss Re's stake has fallen below 10%, it no longer has the right to appoint a non-executive director to the Phoenix board, the FTSE 100-listed long-term savings and retirement business noted. As a result, Christopher Minter will resign from the Phoenix board with effect from the share sale settlement, expected to be around June 25.

The housebuilding sector was lower. Barratt Developments fell 1.7%, Taylor Wimpey gave back 1.4% and Persimmon fell 1.6%.

The UK Competition & Markets Authority said Persimmon and insurer Aviva have committed to refund leasehold homeowners following an industry probe.

Persimmon will allow homeowners to buy the freehold of their home at a discount, while Aviva will remove certain clauses from leasehold contracts and repay those who were affected by them, the regulator said.

Persimmon said all homeowners who have bought a leasehold property since 2000 will be allowed to buy their freehold, for a price capped at GBP2,000. The company also will reimburse customers who already bought their freehold for more than GBP2,000 under an existing scheme.

Aviva, which buys leasehold contracts from housebuilders, has agreed to remove "doubling clauses" and refund those who were affected by them. It will also end ground rents that rise with inflation, meaning those rents will revert to their original price.

Aviva shares were 0.1% lower.

Berkeley fell 1.8%, despite reporting improved annual earnings. The housebuilder cautioned transaction levels in its key London market were hit by travel restrictions and Berkeley's selective approach to market, but was confident as enquiries in the UK capital are now above pre-pandemic levels.

Berkeley's pretax profit in the year ended April 30 was 2.9% higher at GBP518.1 million from GBP503.7 million. Revenue rose 15% to GBP2.20 billion from GBP1.92 billion.

GlaxoSmithKline shares were on the rise, up 1.6%. The pharmaceutical firm outlined a new strategic focus, plans to boost sales and profit in the medium term and a fresh "progressive dividend policy".

In an investor update, GSK said it plans to achieve GBP33 billion in sales by the end of 2031. Over the next five years, it is eyeing a sales climb of more than 5% and more than a 10% hike in adjusted operating profit.

It added it will retain a 20% stake in its upcoming Consumer Healthcare spin-out, a "short-term financial investment, which it intends to monetise in a timely manner".

New York equities are called higher, building on Tuesday's gains. The Dow Jones Industrial Average is called up 0.2%, and both the S&P 500 and Nasdaq Composite are pointed up 0.1%. Federal Reserve Chair Jerome Powell on Tuesday suggested the central bank will only patiently rein in its vast monetary policy support.

Powell stuck to his prepared script during the House hearing and reiterated that the central bank will continue its supportive stance to ensure that the "sustained improvement" since the depths of Covid-19 pandemic is extended.

BDSwiss head of investment research, Marshall Gittler, commented: "Powell didn't say anything different from what he said in his comments after the FOMC meeting: most of the rise in inflation is due to transitory effects arising from the reopening of the economy, but these effects have been larger than they expected and could turn out to be more persistent. He emphasized that the FOMC 'will wait for actual evidence of actual inflation or other imbalances' before hiking rates and not move in response to projections."

Against the yen, the dollar was trading at JPY111.04, up from JPY110.73.

Gold was trading at USD1,783.29 an ounce midday on Wednesday, up against USD1,780.60 late Tuesday.

Wednesday afternoon's economic calendar has the US flash PMI for June at 1445 BST, before new home sales at 1500 BST.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more
14 Nov 2023 17:04

LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI

(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.

Read more
13 Nov 2023 09:47

GSK hails momelotinib opinion from European Medicines Agency committee

(Alliance News) - GSK PLC on Monday announced that a European Medicines Agency panel has given a positive opinion recommending momelotinib to treat myelofibrosis patients with anaemia.

Read more
9 Nov 2023 15:50

UK dividends calendar - next 7 days

Friday 10 November 
Bodycote PLCdividend payment date
Breedon Group PLCdividend payment date
Chesnara PLCdividend payment date
Finsbury Growth & Income Trust PLCdividend payment date
Invesco Bond Income Plus Ltddividend payment date
JPMorgan Emerging Markets Investment Trust PLCdividend payment date
Kerry Group PLCdividend payment date
Merchants Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCspecial dividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Senior PLCdividend payment date
Spectris PLCdividend payment date
Spirax-Sarco Engineering PLCdividend payment date
Travis Perkins PLCdividend payment date
Monday 13 November 
no events scheduled 
Tuesday 14 November 
no events scheduled 
Wednesday 15 November 
Coats Group PLCdividend payment date
Ferguson PLCdividend payment date
JP Morgan Mid Cap Investment Trust PLCdividend payment date
Strategic Equity Capital PLCdividend payment date
Thursday 16 November 
abrdn Property Income Trust Ltdex-dividend payment date
Asian Energy Impact Trust PLCex-dividend payment date
Baillie Gifford Japan Trust PLCex-dividend payment date
BlackRock Greater Europe Investment Trust PLCex-dividend payment date
Bunzl PLCex-dividend payment date
Bytes Technology Group PLCex-dividend payment date
Centrica PLCdividend payment date
Coca-Cola Europacific Partners PLCex-dividend payment date
DX Group PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
GCP Asset Backed Income Fund Ltdex-dividend payment date
GSK PLCex-dividend payment date
Hargreaves Lansdown PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
ICG Enterprise Trust PLCex-dividend payment date
James Halstead PLCex-dividend payment date
Lancashire Holdings Ltdspecial ex-dividend payment date
Majedie Investments PLCex-dividend payment date
Marks & Spencer Group PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
New Star Investment Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Personal Group Holdings PLCdividend payment date
Redrow PLCdividend payment date
Regional REIT Ltdex-dividend payment date
Schroder Oriental Income Fund Ltdex-dividend payment date
Scottish American Investment Co PLCex-dividend payment date
SCS Group PLCex-dividend payment date
Shell PLCex-dividend payment date
Supermarket Income REIT PLCdividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
Unilever PLCex-dividend payment date
Wincanton PLCex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
8 Nov 2023 09:30

LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
2 Nov 2023 10:14

LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.